Compare MRCY & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | HAE |
|---|---|---|
| Founded | 1981 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.8B |
| IPO Year | 1997 | 1996 |
| Metric | MRCY | HAE |
|---|---|---|
| Price | $78.01 | $120.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $114.80 | ★ $122.20 |
| AVG Volume (30 Days) | 568.9K | ★ 605.0K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.08 | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $983,622,000.00 | $910,373,000.00 |
| Revenue This Year | $10.46 | $6.27 |
| Revenue Next Year | $11.44 | $5.86 |
| P/E Ratio | ★ N/A | $165.10 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $65.04 | $48.55 |
| 52 Week High | $128.45 | $121.19 |
| Indicator | MRCY | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 77.14 |
| Support Level | $73.38 | $72.93 |
| Resistance Level | $89.06 | N/A |
| Average True Range (ATR) | 2.31 | 3.12 |
| MACD | 0.00 | 1.24 |
| Stochastic Oscillator | 7.71 | 98.90 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.